COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-mutated NSCLC innovativemedicine.jnj.com/newsroom/cocoo… EGFR Resisters EGFR Positive Lung Cancer UK Exon 20 Group, a multistakeholder organization

In 2025, can we really justify a phase 3 trial for patients with oncogene-addicted #LungCancer without mandatory brain MRIs? It’s time to prioritize patients over chasing poorly analyzed ‘significant’ advantages. We need a real paradigm shift❗️#LCSM

🔑 🇪🇺 #PressRelease EMA CHMP recommends subcutaneous amivantamab (Q2W) for the treatment of patients with advanced EGFR-mutated NSCLC (MARIPOSA & PAPILLON)🪢 #LCSM jnj.com/media-center/p…

Not enough? 🧐

🚨 Don’t miss it! 🚨 Join me, Zofia Piotrowska & Myung-Ju Ahn, tomorrow for a deep dive into this clinically hot topic, for patients with NSCLC harbouring EGFR mutations. Critical insights, real impact—be part of the conversation! See you there! #ELCC25 💡

Don’t miss it!!! We are waiting for you 👇

#ELCC25 ❤️🦋 After a great debate, it’s time to thank my amazing friends & colleagues Zofia and Myung-Ju for an outstanding session on EGFR—standing-room only, not a single seat left! Grateful for such an engaging discussion.🙌

🙌Congrats Marco Pignatelli & team for this amazing research effort, just out in Science Magazine A neuroimmune circuit mediates cancer cachexia-associated apathy science.org/doi/10.1126/sc…

In 1L EGFR-sensitizing (Ex19del, L858R) NSCLC, treatment strategies have evolved from monotherapy TKIs—such as osimertinib (FLAURA), lazertinib (LASER301), and furmonertinib (FURLONG)—to more potent combination regimens. Notable among these are FLAURA2 (osimertinib + chemo) and

Ph3 coming soon….😉

It might have seemed that all three treatment options achieved the same OS… and if that were the case, it could still be useful. But that’s not the case!! And today, fortunately for our patients, the Mariposa study has shown—for the first time in history—a significant OS

#ASCO25 conc Journal of Clinical Oncology 🏮 Zipalertinib in pts With EGFR ex20ins NSCLC Previously Treated With Platinum-B chemo With or Without Amivantamab ascopubs.org/doi/10.1200/JC…

Ph3 trials are always important, be careful not to issue guidance that would eliminate the only well‑established Ph3 data we have. Ph3 studies can change the whole perspective… ▪️Chemo + IO: has never been a standard in this setting ▪️IMpower150: used here and there, but it

ASCO 2025 Annual Meeting #LungCancer Recap - Here are the top trials from #ASCO25 with summary. Follow up for more oncology updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | Stephen V Liu, MD | Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ |

It was truly great to reconnect and discuss the latest in #lungcancer at this year’s CIOT in Venice. So many friends, global KOLs, and valuable time well spent advancing progress in lung cancer. #CIOT25

🔬 Don’t miss AnswersinCME symposium at #WCLC25! Drs Califano, Girard & Passaro dive into HER2+ NSCLC & how it's reshaping treatment outcomes. 📅 Sat, Sept 6 🕥 10:30–11:30 CEST #LungCancer #NSCLC #Oncology

What a wonderful photo; a perfect memory of this amazing #ESMO25 #lungcancer community. Grateful for the energy, friendship, and shared passion that make every moment special.

🚀 EGFR-mutant lung cancer: the landscape is being rewritten. #ESMO25 Read the full post here ⤵️ linkedin.com/posts/antonio-…

Out now in Annals of Oncology👇 When the control arm is already a great option, detecting progress requires more than a HR, and this is particularly true for 1st line combos in #EGFRve #NSCLC Our RMST reanalysis led by Fabian Acker of FLAURA2 & MARIPOSA highlights delayed but